allogeneic processed thymus tissue sold brand name rethymic thymus tissue medical therapy used treatment children congenital takes six months longer reconstitute immune function treated common adverse reactions include high blood pressure cytokine release syndrome low blood magnesium levels rash low platelets graft versus host approved medical use united states october allogeneic processed thymus tissue first thymus tissue product approved us food drug administration allogeneic processed thymus tissue composed human allogeneic donorderived thymus tissue processed cultured implanted people help reconstitute immunity improve immune function people dosing patient customized determined surface area allogeneic processed thymus tissue slices body surface area allogeneic processed thymus tissue indicated immune reconstitution children congenital safety efficacy allogeneic processed thymus tissue established clinical studies included participants ages one month years received single administration allogeneic processed thymus tissue allogeneic processed thymus tissue improved survival people congenital athymia people treated product survived least two us food drug administration fda granted application allogeneic processed thymus tissue rare pediatric disease voucher granted approval rethymic enzyvant therapeutics article incorporates public domain material united states department health human services httpsenwikipediaorgwikiallogeneicprocessedthymustissue